Koers Immunovant, Inc. Nasdaq
Aandelen
US45258J2015
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | 14,41 mln. 13,28 mln. | Marktkapitalisatie | 4,49 mld. 4,13 mld. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -250 mln. -230 mln. | Nettowinst (verlies) 2025 * | -276 mln. -254 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | 653 mln. 601 mln. | Nettoliquiditeiten 2025 * | 532 mln. 490 mln. | EV/omzet 2025 * | 274 x |
K/w-verhouding 2024 * |
-17,3
x | K/w-verhouding 2025 * |
-16,9
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 42,43% |
Recentste transcriptie over Immunovant, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 01-06-19 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 04-10-21 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 18-12-19 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 18-12-19 |
Douglas Hughes
BRD | Director/Board Member | 62 | 18-12-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+44,48% | 54,04 mld. | |
+43,57% | 41,96 mld. | |
-0,86% | 41,92 mld. | |
-7,59% | 28,35 mld. | |
+12,30% | 26,35 mld. | |
-21,83% | 19 mld. | |
+7,15% | 13 mld. | |
+29,40% | 12,28 mld. | |
+25,15% | 12,19 mld. |